News

News

Long-Term Study Confirms Durable Responses With Reduced-Intensity Conditioning AlloHCT in High-Risk CLL

Ten-year follow-up data from the prospective phase II CLL3X trial of the German CLL Study Group confirms that patients with high-risk chronic lymphocytic leukemia...
WIB_icon

Population-Based Study Finds Persistent Gaps in Understanding and Identification of VTE Risk

An estimated 500,000 venous thromboembolism (VTE) events occur annually in the United States, about half of which are related to current or recent hospitalizations,...
WIB_icon

Isatuximab Plus Lenalidomide and Dexamethasone Active in Relapsed/Refractory Multiple Myeloma

Treatment with the investigational anti-CD38 monoclonal antibody isatuximab (in combination with lenalidomide and dexamethasone) led to an overall response rate (ORR) of 51 percent...

ASH Co-Hosts Congressional Briefing on Sickle Cell Disease, Blood Journal’s Impact On the Rise,...

ASH Co-Hosts Congressional Briefing on Sickle Cell DiseaseThe American Society of Hematology (ASH) co-hosted a congressional briefing on sickle cell disease (SCD) and gene...

Remembering H. Jean Khoury, NCI Funds Standardization of Cancer Genomic Data, and more

Remembering H. Jean Khoury (1967-2017) H. Jean Khoury, MD, an expert in hematologic malignancies at the Winship Cancer Institute of Emory University, died at age...

Pembrolizumab Safe and Effective in Heavily Pretreated Patients With Classic Hodgkin Lymphoma

Though the standard of care for patients with relapsed/refractory classic Hodgkin lymphoma (cHL) induces high rates of response, duration of response is estimated to...

FDA Panel Shows Support for Epoetin Biosimilar

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 14-1 to recommend approval of an epoetin alfa biosimilar agent. If approved by the FDA, this...

FDA Accepts New Drug Application for CPX-351 for AML

The FDA has accepted a new drug application (NDA) for CPX-351 – a liposomal formulation of cytarabine and daunorubicin encapsulated at a 5:1 molar...

Number of Physicians Who Own Their Own Practices Drops

The AMA’s biannual practice survey shows that the proportion of physicians who have an ownership stake in their own practices fell to 47.1 percent...

AMA Considers Backing the Disclosure of Drug Prices on Consumer Ads

Direct-to-consumer (DTC) advertising became legal in the United States in 1997 but has been debated ever since, with some groups claiming that this type...
Advertisement

Current Issue

July Bonus Mid-Year Edition

This bonus issue features conversations with families joined by hematology, highlights from recent hematology/oncology meetings, and more.